IVBXF (Innovent Biologics) Total Current Assets : $1,523 Mil (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Innovent Biologics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Innovent Biologics's total current assets for the quarter that ended in Jun. 2024 was $1,523 Mil.

Innovent Biologics Total Current Assets Historical Data

The historical data trend for Innovent Biologics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Total Current Assets Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

777.82

1,447.66

1,813.52

1,650.49

1,880.62

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Current Assets	Get a 7-Day Free Trial											1,672.02	1,650.49	1,589.82	1,880.62	1,522.97

Innovent Biologics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Innovent Biologics's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1417.297	+	208.715	+	135.583	+	119.022
	=	1,881

Innovent Biologics's Total Current Assets for the quarter that ended in Jun. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1162.896	+	238.396	+	95.167	+	26.507
	=	1,523

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Innovent Biologics (OTCPK:IVBXF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Innovent Biologics's Liquidation Value for the quarter that ended in Jun. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1162.896	-	1084.721	+	0.75 * 188.697	+	0.5 * 95.167
=	267

Innovent Biologics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (OTCPK:IVBXF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

IVBIY:USA 01801:Hong Kong 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.